Byetta Lawsuit Claims Move Forward with Recent Findings of Pancreatitis Among Users
A study examining the effects certain incretin mimetics have on the pancreas may lend evidence to the growing body of Byetta lawsuit filings now underway in the U.S.
Findings of the research, which looked at 1,169 complaints found on the Italian Spontaneous ADR Reporting Database, were published online at Informa Healthcare on November 13th. Of those adverse event reports, 90 alleged pancreatitis or elevated levels of the pancreatic enzyme, leading authors to conclude that individuals taking Byetta should be monitored for these types of injury.
This study is the latest to shed light on the dangers of incretin mimetics as they continue to be mentioned in the news. Right now, 150 cases involving Byetta, Januvia, Victoza and other medications part of this class of Type 2 diabetes drugs are pending in a federal litigation established in the U.S. District Court, Southern District of California. These lawsuits were brought on behalf of individuals who allegedly developed Byetta pancreatic cancer, pancreatitis and other injuries, and now similarly allege that its manufacturer failed to adequately warn diabetics and their doctors about the serious risks associated with its product. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
Byetta Lawsuit Litigation Moves Forward
Approved in 2005, Byetta was the first incretin mimetic to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of Type 2 diabetes. Concerns began just three years later though, when the federal agency led a Safety Communication to alert the public that it received numerous pancreatitis reports from users. In February 2011, a report in Gastroenterology then found a 3-fold increased risk for pancreatic cancer among Byetta users, who were also six times more likely to develop pancreatitis. 30 instances of thyroid cancer were also recorded.
Information about these illnesses is continuing to develop as the Byetta lawsuit litigation moves forward. According to an Order issued on November 5th, the Court approved certain protocol for In Extremis depositions, which will allow plaintiffs to schedule depositions early if they are “reasonably near the end of life.” This may relate to life-threatening cases of Byetta pancreatic cancer and/or pancreatitis, lawsuits allege.
Contact an Attorney to Learn More about the Growing Byetta Lawsuit Litigation
Call the lawyers at Bernstein Liebhard LLP to learn more about Byetta lawsuit claims, and whether you may be eligible to file a lawsuit against the manufacturer of this incretin mimetic. Call the Firm for more details at (877) 779-1414.